Antibacterial Drugs Market Share Expand To US$ 44,063.3 Million By Top Manufacturers, Latest Technologies, Segments Overview, Future Trends, Growth Opportunity and Forthcoming Developments

Antibacterial drugs are primarily used in the treatment and prevention of infectious diseases. Antibacterial drugs function by destroying or inhibiting microbial growth in the body.

The global antibacterial drugs market size was valued at US$ 42,048.3 Mn in 2020 and is expected to exhibit a CAGR of 0.7% over the forecast period (2020 – 2027).

Request to download and view Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/177

Growing incidences of infectious diseases are projected to propel the growth of the antibacterial drugs market

Antibacterial drugs are used in the treatment of infection caused by various bacteria such as Escherichia coli, Klebsiella pneumonia, and others. Moreover, growing incidences of infectious diseases such as tuberculosis, hepatitis B, leprosy, typhoid, malaria, HIV/AIDS and others are projected to fuel the market growth. According to the World Health Organization (WHO) November 2018 factsheet, an estimated 219 million people were diagnosed by malaria in 2017, in 19 countries.

Moreover, rising initiatives by government subjected to a growing number of infectious disease around the globe is expected to propel market growth over the forecast period. For instance, in May 2018, the UK government announced a fund of US$ 34 million to fight against antimicrobial resistance (AMR). This funding will be distributed to the 4 projects such as Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator of US$ 23 million, Global Antibiotic Research and Development Partnership invested US$ 1 million, and US$ 5 million for two projects such as a bilateral partnership with Argentina and Foundation for Innovative New Diagnostics.

Quick Buy – Antibacterial Drugs Market Research Report: https://www.coherentmarketinsights.com/insight/buy-now/177

Increasing population base rate and high incidences of infectious diseases in North America are projected to foster regional market growth

North America holds a dominant position in the global antibacterial drugs market, and this can be attributed to the rising population base susceptible to infectious diseases and high incidences of infectious diseases such as tuberculosis and others. According to the Centers for Disease Control and Prevention (CDC), in 2017, an estimated 9,105 patients were diagnosed with tuberculosis in the U.S.

Moreover, an increasing number of drug approval by the U.S. Food and Drug Administration (FDA) is also expected to boost market growth. For instance, in February 2019, Novartis received the U.S. Food and Drug Administration (FDA) approval for Egaten, used for the treatment of Fascioliasis caused by Fasciola hepatica infection.

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/antibacterial-drugs-market-to-surpass-us-497-billion-by-2026-134

Key Players

Major players operating in the global antibacterial drugs market include Novartis AG, Allergan, Bristol Myers Squibb Company, AstraZeneca, Johnson and Johnson, Merck & Co., Inc., GlaxoSmithKline Plc. (GSK), Sanofi SA, Bayer AG, and Pfizer Inc

Table of Contents

1. Research Objective and Assumption
   • Research Objectives
   • Assumptions
   • Abbreviations
2. Market Purview
   • Report Description
     • Market Definition and Scope
   • Executive Summary
     • Market Snippet, By Drug Class
     • Market Snippet, By Distribution Channel
   • Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
   • Impact Analysis
   • Key Developments
   • Technological Advancement
   • Regulatory Scenario
   • Pipeline Analysis
4. Global Antibacterial Drugs Market, By Drug Class, 2017 – 2027 (US$ Mn)
   • Introduction
     • Market Share Analysis, 2019 and 2027 (%)
     • Y-o-Y Growth Analysis, 2019–2027
     • Segment Trends
   • β-lactams
   • Quinolones
   • Macrolides
   • Tetracyclines
   • Aminoglycosides
   • Sulfonamides
   • Phenicols
5. Global Antibacterial Drugs Market, By Distribution Channel, 2017 – 2027 (US$ Mn)
   • Introduction
     • Market Share Analysis, 2019 and 2027 (%)
     • Y-o-Y Growth Analysis, 2019–2027
     • Segment Trends
   • Hospital Pharmacies
   • Retail Pharmacies
   • Online Pharmacies
6. Global Antibacterial Drugs Market, By Regions, 2017 – 2027 (US$ Mn)
   • Introduction
     • Market Share Analysis, 2019 and 2027 (%)
     • Y-o-Y Growth Analysis, 2019–2027
     • Segment Trends
   • North America
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
       • U.S.
       • Canada
   • Europe
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
       • U.K.
       • Germany
       • Italy
       • France
       • Spain
       • Russia
       • Rest of Europe
   • Asia Pacific
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
       • China
       • India
       • Japan
       • ASEAN
       • Australia
       • South Korea
       • Rest of Asia Pacific
   • Latin America
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
       • Brazil
       • Mexico
       • Argentina
       • Rest of Latin America
   • Middle East
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
       • GCC
       • Israel
       • Rest of Middle East
   • Africa
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
       • North Africa
       • Central Africa
       • South Africa
7. Competitive Landscape
   • Company Profiles
     • Shionogi Inc.
       • Company Overview
       • Product Portfolio
       • Key Developments
       • Financial Performance
       • Strategies
     • Iterum Therapeutics plc
     • Kyorin Pharmaceutical Co., Ltd.
     • Allecra Therapeutics GmbH
     • Wockhardt Ltd.
     • Theravance Biopharma, Inc.
     • R-Pharm Group
     • Entasis Therapeutics
     • Melinta Therapeutics
     • Micurx Pharmaceutical Inc.
     • Debiopharm Group
     • Boston Pharmaceuticals Inc.
     • TenNor Therapeutics
     • Sichuan Pharmaceutical Co., Ltd.
     • Other Major Players
8. Section
   • References
   • Research Methodology
   • About us and Sales Contact

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837